Table 1.

Characteristics of 2,439 men initially diagnosed with nonmetastatic prostate cancer in the HPFS and the PHS

HPFSPHSTotal
Number of participants1,2061,2332,439
Date of diagnosis (median, IQR)1999 (1997, 2002)1995 (1991, 1999)1998 (1994, 2001)
Age at diagnosis, y (mean ± SD)70 ± 770 ± 770 ± 7
Smoking status at blood draw (%)
 Never504849
 Former, quit ≥10 y383637
 Former, quit <10 y81110
 Current344
 Missing100
BMI at blood draw (%)
 <25 kg/m2505955
 25–29.9 kg/m2413940
 ≥30 kg/m2835
Gleason sum at diagnosis (%)
 <7525956
 7352329
 ≥8111111
 Missing275
Clinical stage T3, %264
PSA at diagnosis, ng/mL (median, IQR)7 (5, 10)7 (5, 12)7 (5, 11)
α-tocopherol, mg/L (median, IQR)12.3 (9.0, 16.5)11.1 (9.2, 13.7)11.4 (9.1, 14.6)
γ-tocopherol, mg/L (median, IQR)1.5 (0.9, 2.3)1.9 (1.4, 2.5)1.8 (1.2, 2.4)
Lycopene, ng/mL (median, IQR)396 (291, 539)313 (210, 474)352 (239, 507)
Time from blood draw to diagnosis, y (median, IQR)6 (3, 8)13 (9, 17)8 (5, 13)
Metastases or deaths due to prostate cancer, N (%)84 (7)139 (11)223 (9)